Partner at Novo's venture fund sued over unsuccessful billion-kroner investment
Thomas Dyrberg, managing partner in Novo Ventures, is one of eight people being sued in an American case over alleged misleading of investors in the botched biotech firm Ophthotech, which at one point was Novo Ventures’ biggest single investment.
BY KEVIN GRØNNEMANN
It was, to use Thomas Dyrberg's own words, a "huge disappointment and a big surprise," when biotech firm Ophthotech was forced to admit in December 2016 that its largest project, the potential drug Fovista, was unusable.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
